Development of Calcium Sulfate-Based Bone Substitutes with Antimicrobial Properties for Orthopedic Bone Reconstructions

• Grant number: 25/02532-7
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: January 01, 2026
• End date: December 31, 2027
• Field of knowledge: Engineering - Biomedical Engineering - Bioengineering
• Principal Investigator: Karen Julie Santos Grancianinov Costa
• Grantee: Karen Julie Santos Grancianinov Costa
• Principal investigators: Daniela Rodrigues de Melo ; Felipe Lopes Bisson ; Rayssa do Nascimento Bezerra
• Associated researchers: Ivone Regina de Oliveira ; Tiago Moreira Bastos Campos

Abstract

Regenerative medicine has gained prominence in orthopedics due to its broad application in treating bone defects caused by trauma, diseases, tumors, and other conditions. Bone regeneration, essential for restoring these defects, can be facilitated by synthetic biomaterials, which have proven to be effective alternatives for filling defects of various shapes and sizes. Calcium sulfate is a widely used synthetic biomaterial due to its biocompatibility and long-standing clinical history. However, its rapid dissolution in physiological environments limits its standalone application in cases requiring prolonged support for bone regeneration. To address this limitation, combining calcium sulfate with osteoconductive biomaterials has shown significant improvements in mechanical strength, bioactivity, and resorption rate. In this context, Bioactive proposes the development of an innovative three-phase biomaterial that integrates calcium sulfate hemihydrate (¿ and ¿), hydroxyapatite, ¿-tricalcium phosphate, and antimicrobial agents. This formulation is designed to optimize physicochemical and biological properties, providing a more effective solution for bone reconstruction compared to existing market options. Additionally, bacterial infections remain a major challenge in orthopedic surgeries. Studies indicate that antimicrobial agents such as silver, zinc, and strontium not only combat infections, including those caused by resistant bacteria, but also stimulate bone regeneration. Therefore, this project aims to develop advanced biomaterials with antimicrobial and osteoinductive properties, ensuring safer and more efficient treatment for patients with osteoporosis or bone defects. Beyond scientific advancement, Bioactive seeks to establish itself in the biomaterials market by not only driving innovation but also making high-impact, value-added products accessible. This strategic approach positions Bioactive as a superior treatment alternative for patients with osteoporosis or bone defects. (AU)